A pilot open-label trial of minocycline in patients with autism and regressive features

Table 3 Treatment effect on cytokines, chemokines, metalloproteinases and growth factors ^a

Analyte	Cerebrospinal fluid (CSF)		Serum		Plasma
Analyte	Z	P	Z	P	Z	P
TNFα	−0.45	0.66	−1.78	0.074
IL-6	−0.36	0.72	−1.75	0.08
CCL2 (MCP-1)	−1.78	0.075	−1.27	0.24
CCL3 (MIP-1α)	−0.18	0.86	−0.76	0.45
CCL5 (RANTES)	−0.73	0.47	0.66	0.61
CXCL8 (IL-8)	−0.45	0.66	−1.99	0.047
BDNF^b	−2.03	0.042			−0.76	0.45
Truncated-BDNF/α-2 M^c			−2.19	0.028
Mature-BDNF/α-2 M ^c			−0.87	0.386
CD40L	−0.89	0.37			−1.33	0.18
GDNF	−0.37	0.71			−1.83	0.07
HGF	−2.19	0.028			−1.25	0.21
Leptin	−1.48	0.14			−0.27	0.79
MMP-1					−1.07	0.29
MMP-3					−0.15	0.88
MMP-7					−1.89	0.059
MMP-8					−0.05	0.96
MMP-9					−1.38	0.17

^aSelected analytes, Mann–Whitney U-test.
^bQuantified by Luminex technique. In CSF only the truncated-BDNF form appears to be detectable in immunobotting experiments.
^cQuantified by immunoblotting and densitometry analysis. Significance was calculated based on ratio BDNF isoform/α-2 M.

ISSN: 1866-1955